SCHEMBL3405116

SCHEMBL3405116

Cc1nc(-c2ccccc2Cl)sc1C(=O)N1CCC(N2CCCCCC2)CC1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 7/20 0.60
HRH3 Q9Y5N1 2/20 0.53
LMNA P02545 1/20 0.48
NPC1 O15118 1/20 0.47
ALDH1A1 P00352 1/20 0.47
MAPT P10636 1/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
L3MBTL3 Q96JM7 3/20 0.47
L3MBTL1 Q9Y468 3/20 0.47
TP53BP1 Q12888 1/20 0.47
CNR1 P21554 1/20 0.47
POLB P06746 1/20 0.47
CES2 O00748 1/20 0.46
PPARD Q03181 1/20 0.46
PPARA Q07869 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13071743 1.00 HTR2C (0.60) HTR2CHRH3LMNANPC1ALDH1A1
SCHEMBL3404914 0.92 HTR2C (0.58) HTR2CHRH3LMNAALDH1A1MAPT
SCHEMBL3400795 0.92 HTR2C (0.58) HTR2CHRH3LMNAALDH1A1MAPT
SCHEMBL3398198 0.91 HTR2C (0.55) HTR2CHRH3LMNANPC1ALDH1A1
SCHEMBL13071662 0.90 HTR2C (0.62) HTR2CHRH3LMNAL3MBTL3L3MBTL1
SCHEMBL3399560 0.90 HTR2C (0.62) HTR2CHRH3LMNAL3MBTL3L3MBTL1
SCHEMBL13071740 0.89 HTR2C (0.61) HTR2CHRH3LMNAL3MBTL3L3MBTL1
SCHEMBL3404356 0.89 HTR2C (0.61) HTR2CHRH3LMNAALDH1A1L3MBTL3
SCHEMBL3405780 0.88 HTR2C (0.50) HTR2CHRH3LMNANPC1ALDH1A1
SCHEMBL3398930 0.88 HTR2C (0.50) HTR2CHRH3LMNAALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100297035-A1 Thiazole Amides, Imidazole Amides and Related Analogues LIGAND PHARMACEUTICALS, INC. (US) 2010-11-25 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
WO-2006089076-A9 THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGUES NEUROGEN CORP (US) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100297035-A1 Thiazole Amides, Imidazole Amides and Related Analogues HRH3, HRH4, HRH2 HTR2C 416/4885HRH3 1/4885LMNA 4548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.